• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

通过亲和标记法对表皮生长因子主要受体结合域进行定位

Localization of a major receptor-binding domain for epidermal growth factor by affinity labeling.

作者信息

Lax I, Burgess W H, Bellot F, Ullrich A, Schlessinger J, Givol D

机构信息

Rorer Biotechnology, Inc., Rockville, Maryland 20850.

出版信息

Mol Cell Biol. 1988 Apr;8(4):1831-4. doi: 10.1128/mcb.8.4.1831-1834.1988.

DOI:10.1128/mcb.8.4.1831-1834.1988
PMID:3260004
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC363348/
Abstract

Epidermal growth factor (EGF) receptor was affinity labeled with 125I-labeled EGF, using bifunctional covalent cross-linking agents. The affinity-labeled receptor was isolated and cleaved with CNBr to yield a single-labeled fragment, which was unequivocally identified by site-specific antibodies and other methods to encompass residues 294 to 543 of the EGF receptor. On the basis of amino acid sequence conservation, the extracellular portion of EGF receptor can be divided into four domains. The labeled CNBr fragment contains the entire sequence which is flanked by the two cysteine-rich domains of extracellular portion of the EGF receptor denoted as domain III. On the basis of these and other results, we propose that domain III contributes most of the interactions that define ligand-binding specificity of the EGF receptor.

摘要

利用双功能共价交联剂,用¹²⁵I标记的表皮生长因子(EGF)对表皮生长因子受体进行亲和标记。分离出亲和标记的受体,并用溴化氰裂解,得到一个单标记片段,通过位点特异性抗体和其他方法明确鉴定该片段包含表皮生长因子受体的294至543位残基。根据氨基酸序列保守性,表皮生长因子受体的细胞外部分可分为四个结构域。标记的溴化氰片段包含整个序列,该序列两侧是表皮生长因子受体细胞外部分的两个富含半胱氨酸的结构域,称为结构域III。基于这些及其他结果,我们提出结构域III对定义表皮生长因子受体配体结合特异性的大部分相互作用起作用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f145/363348/34d65456c230/molcellb00064-0461-b.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f145/363348/a51803f37fac/molcellb00064-0460-a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f145/363348/a5d1ef347e4a/molcellb00064-0461-a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f145/363348/34d65456c230/molcellb00064-0461-b.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f145/363348/a51803f37fac/molcellb00064-0460-a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f145/363348/a5d1ef347e4a/molcellb00064-0461-a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f145/363348/34d65456c230/molcellb00064-0461-b.jpg

相似文献

1
Localization of a major receptor-binding domain for epidermal growth factor by affinity labeling.通过亲和标记法对表皮生长因子主要受体结合域进行定位
Mol Cell Biol. 1988 Apr;8(4):1831-4. doi: 10.1128/mcb.8.4.1831-1834.1988.
2
Human epidermal growth factor receptor residue covalently cross-linked to epidermal growth factor.与人表皮生长因子共价交联的人表皮生长因子受体残基。
Proc Natl Acad Sci U S A. 1990 Apr;87(8):3151-5. doi: 10.1073/pnas.87.8.3151.
3
High-yield covalent attachment of epidermal growth factor to its receptor by kinetically controlled, stepwise affinity cross-linking.
Biochemistry. 1992 Aug 18;31(32):7341-6. doi: 10.1021/bi00147a019.
4
Human epidermal growth factor (EGF) receptor sequence recognized by EGF competitive monoclonal antibodies. Evidence for the localization of the EGF-binding site.表皮生长因子(EGF)竞争性单克隆抗体识别的人表皮生长因子(EGF)受体序列。EGF结合位点定位的证据。
J Biol Chem. 1989 Oct 15;264(29):17469-75.
5
Direct identification of residues of the epidermal growth factor receptor in close proximity to the amino terminus of bound epidermal growth factor.直接鉴定与结合的表皮生长因子氨基末端紧邻的表皮生长因子受体残基。
Proc Natl Acad Sci U S A. 1992 Aug 15;89(16):7801-5. doi: 10.1073/pnas.89.16.7801.
6
Localization by photoaffinity labeling of natriuretic peptide receptor-A binding domain.通过光亲和标记法对利钠肽受体-A结合域进行定位
Biochemistry. 1996 Oct 1;35(39):12950-6. doi: 10.1021/bi960818q.
7
Inhibition of apolipoprotein B secretion by IL-6 is mediated by EGF or an EGF-like molecule in CaCo-2 cells.
J Lipid Res. 1997 Feb;38(2):206-16.
8
Functional analysis of the ligand binding site of EGF-receptor utilizing chimeric chicken/human receptor molecules.利用鸡/人嵌合受体分子对表皮生长因子受体配体结合位点进行功能分析。
EMBO J. 1989 Feb;8(2):421-7. doi: 10.1002/j.1460-2075.1989.tb03393.x.
9
A 40-kDa epidermal growth factor/transforming growth factor alpha-binding domain produced by limited proteolysis of the extracellular domain of the epidermal growth factor receptor.一种通过对表皮生长因子受体胞外域进行有限蛋白酶解产生的40千道尔顿表皮生长因子/转化生长因子α结合结构域。
J Biol Chem. 1993 Jan 25;268(3):1976-81.
10
Ligand-induced stimulation of epidermal growth factor receptor mutants with altered transmembrane regions.
Proc Natl Acad Sci U S A. 1988 Dec;85(24):9567-71. doi: 10.1073/pnas.85.24.9567.

引用本文的文献

1
Conformational diversity and protein-protein interfaces in drug repurposing in Ras signaling pathway.在 Ras 信号通路中重新利用药物时的构象多样性和蛋白质-蛋白质界面。
Sci Rep. 2024 Jan 12;14(1):1239. doi: 10.1038/s41598-023-50913-8.
2
An overview of resistance to Human epidermal growth factor receptor 2 (Her2) targeted therapies in breast cancer.乳腺癌中对人表皮生长因子受体2(Her2)靶向治疗的耐药性概述。
Cancer Drug Resist. 2022 Jun 1;5(2):472-486. doi: 10.20517/cdr.2022.09. eCollection 2022.
3
Integration of liquid biopsy and pharmacogenomics for precision therapy of EGFR mutant and resistant lung cancers.

本文引用的文献

1
Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells.人表皮生长因子受体cDNA序列及扩增基因在A431表皮样癌细胞中的异常表达。
Nature. 1984;309(5967):418-25. doi: 10.1038/309418a0.
2
Direct linkage of EGF to its receptor: characterization and biological relevance.
J Supramol Struct. 1980;14(4):441-59. doi: 10.1002/jss.400140404.
3
Glycosylation of the epidermal growth factor receptor in A-431 cells. The contribution of carbohydrate to receptor function.
J Biol Chem. 1984 Oct 25;259(20):12586-94.
4
液体活检与药物基因组学相结合,实现 EGFR 突变及耐药肺癌的精准治疗。
Mol Cancer. 2022 Feb 24;21(1):61. doi: 10.1186/s12943-022-01534-8.
4
Emerging anti-cancer antibodies and combination therapies targeting HER3/ERBB3.新兴的靶向HER3/ERBB3的抗癌抗体及联合疗法
Hum Vaccin Immunother. 2016 Mar 3;12(3):576-92. doi: 10.1080/21645515.2015.1102809. Epub 2015 Nov 3.
5
Examination of HER3 targeting in cancer using monoclonal antibodies.使用单克隆抗体检测癌症中HER3靶点
Proc Natl Acad Sci U S A. 2015 Jan 20;112(3):839-44. doi: 10.1073/pnas.1423645112. Epub 2015 Jan 6.
6
Reversion of the ErbB malignant phenotype and the DNA damage response.逆转 ErbB 恶性表型和 DNA 损伤反应。
Exp Mol Pathol. 2012 Dec;93(3):324-33. doi: 10.1016/j.yexmp.2012.09.007. Epub 2012 Sep 27.
7
Time-resolved fluorescence resonance energy transfer (TR-FRET) to analyze the disruption of EGFR/HER2 dimers: a new method to evaluate the efficiency of targeted therapy using monoclonal antibodies.时间分辨荧光共振能量转移(TR-FRET)分析 EGFR/HER2 二聚体的破坏:一种评估单克隆抗体靶向治疗效率的新方法。
J Biol Chem. 2011 Apr 1;286(13):11337-45. doi: 10.1074/jbc.M111.223503. Epub 2011 Jan 31.
8
The tethering arm of the EGF receptor is required for negative cooperativity and signal transduction.EGF 受体的连接臂对于负协同作用和信号转导是必需的。
J Biol Chem. 2011 Jan 14;286(2):1545-55. doi: 10.1074/jbc.M110.182899. Epub 2010 Nov 3.
9
The role of HER2 in cancer therapy and targeted drug delivery.HER2 在癌症治疗和靶向药物递送中的作用。
J Control Release. 2010 Sep 15;146(3):264-75. doi: 10.1016/j.jconrel.2010.04.009. Epub 2010 Apr 10.
10
Directing traffic in neural cells: determinants of receptor tyrosine kinase localization and cellular responses.引导神经细胞中的交通:受体酪氨酸激酶定位和细胞反应的决定因素。
J Neurochem. 2008 Jun 1;105(6):2055-68. doi: 10.1111/j.1471-4159.2008.05263.x.
Allosteric regulation of the epidermal growth factor receptor kinase.表皮生长因子受体激酶的变构调节
J Cell Biol. 1986 Dec;103(6 Pt 1):2067-72. doi: 10.1083/jcb.103.6.2067.
5
Protein-tyrosine kinases.蛋白质酪氨酸激酶
Annu Rev Biochem. 1985;54:897-930. doi: 10.1146/annurev.bi.54.070185.004341.
6
Antibodies against a synthetic peptide as a probe for the kinase activity of the avian EGF receptor and v-erbB protein.抗合成肽抗体作为禽类表皮生长因子受体和v-erbB蛋白激酶活性探针。
Cell. 1985 Mar;40(3):619-25. doi: 10.1016/0092-8674(85)90210-7.
7
Epidermal growth factor.表皮生长因子
Annu Rev Biochem. 1979;48:193-216. doi: 10.1146/annurev.bi.48.070179.001205.